Журнал кардиореспираторных исследований 2026. №2/1

Maqola mavzusi

Yurak ishemik kasalligi rivojlanishida buyrak funksiyasi buzilishining klinik-prognostik ahamiyati va sun’iy intellekt asosida klinik qaror qabul qilish tizimini ishlab chiqish (83-87)

Mualliflar

E.N. Tashkenbayeva, S.N. Muxtarov, E.E. Ergashzoda

Muassasa

Samarqand davlat tibbiyot universiteti, RIKIATMSVMF

Annotatsiya

Yurak ishemik kasalligi (YuIK) va surunkali buyrak kasalligi (SBK) hozirgi kunda yagona kardiorenal kontinuumning o‘zaro bog‘liq komponentlari sifatida qaralmoqda. Buyrak funksiyasining buzilishi, jumladan, glomerulyar filtratsiya tezligining pasayishi va albuminuriya, YuIK bilan og‘rigan bemorlarda noqulay prognozning mustaqil omili hisoblanadi. Zamonaviy tadqiqotlar shuni ko‘rsatadiki, SBKning hatto dastlabki bosqichlari ham yurak-qon tomir asoratlari, gospitalizatsiya va o‘lim xavfining oshishi bilan bog‘liq. Ushbu maqolada kardiorenal o‘zaro ta’sirning patogenetik mexanizmlari hamda buyrak biomarkerlari asosida xavfni stratifikatsiya qilish masalalari yoritilgan. KDIGO 2024 va ESC 2024 tavsiyalariga alohida e’tibor qaratilib, kompleks yondashuv zarurligi ta’kidlangan. Shuningdek, sun’iy intellekt asosida klinik qaror qabul qilish tizimlarini yaratish istiqbollari ko‘rib chiqilgan.

Kalit so'zlar

yurak ishemik kasalligi; surunkali buyrak kasalligi; kardiorenal sindrom; glomerulyar filtratsiya tezligi; albuminuriya; sun’iy intellekt

Adabiyotlar

1. Rangaswami J., Bhalla V., Blair J.E.A. et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies // Circulation. – 2019. – Vol. 139(16). – P. e840–e878. – DOI: 10.1161/CIR.0000000000000664 2. Ronco C., McCullough P., Anker S.D. et al. Cardiorenal syndromes: report from the consensus conference // European Heart Journal. – 2018. – Vol. 39(22). – P. 1951–1960. – DOI: 10.1093/eurheartj/ehy210 3. House A.A., Wanner C., Sarnak M.J. et al. Chronic kidney disease and cardiovascular disease // Lancet. – 2019. – Vol. 393(10180). – P. 1757– 1768. – DOI: 10.1016/S0140-6736(19)30076-5 4. Matsushita K., van der Velde M., Astor B.C. et al. Association of estimated glomerular filtration rate and albuminuria with mortality and cardiovascular outcomes // Lancet. – 2016. – Vol. 375(9731). – P. 2073–2081. – DOI: 10.1016/S0140-6736(16)30503-1 5. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events // New England Journal of Medicine. – 2018. – Vol. 351. – P. 1296–1305. – DOI: 10.1056/NEJMoa041031 6. Ndumele C.E., Rangaswami J., Chow S.L. et al. Cardiovascular-Kidney-Metabolic health // Circulation. – 2023. – Vol. 147. – P. e720–e759. – DOI: 10.1161/CIR.0000000000001123 7. KDIGO 2021 Clinical Practice Guideline for the Management of CKD // Kidney International Supplements. – 2021. – Vol. 11(1). – P. 1–150. – DOI: 10.1016/j.kisu.2020.12.001 8. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD // Kidney International. – 2020. – Vol. 98(4S). – P. S1–S115. – DOI: 10.1016/j.kint.2020.06.019 9. McDonagh T.A., Metra M., Adamo M. et al. ESC Guidelines for heart failure // European Heart Journal. – 2021. – Vol. 42. – P. 3599–3726. – DOI: 10.1093/eurheartj/ehab368 10. Knuuti J., Wijns W., Saraste A. et al. ESC Guidelines for chronic coronary syndromes // European Heart Journal. – 2019. – Vol. 41. – P. 407–477. – DOI: 10.1093/eurheartj/ehz425 11. Braunwald E. Gliflozins in cardiovascular disease // Journal of the American College of Cardiology. – 2022. – Vol. 79. – P. 2022–2032. – DOI: 10.1016/j.jacc.2022.02.004 12. Heerspink H.J.L., Stefansson B.V., Correa-Rotter R. et al. Dapagliflozin in patients with CKD // New England Journal of Medicine. – 2020. – Vol. 383. – P. 1436–1446. – DOI: 10.1056/NEJMoa2024816 13. Perkovic V., Jardine M.J., Neal B. et al. Canagliflozin and renal outcomes // New England Journal of Medicine. – 2019. – Vol. 380. – P. 2295–2306. – DOI: 10.1056/NEJMoa1811744 14. Zannad F., Ferreira J.P., Pocock S.J. et al. SGLT2 inhibitors in heart failure // Lancet. – 2020. – Vol. 396. – P. 819–829. – DOI: 10.1016/S0140-6736(20)31824-9 15. Levin A., Stevens P.E., Bilous R.W. et al. Kidney disease: improving global outcomes // Kidney International. – 2017. – Vol. 91. – P. 19– 62. – DOI: 10.1016/j.kint.2016.10.019 16. Fox C.S., Matsushita K., Woodward M. et al. Associations of kidney disease measures with mortality // JAMA. – 2017. – Vol. 307. – P. 2025–2035. – DOI: 10.1001/jama.2017.1683 17. Briasoulis A., Bakris G.L. Chronic kidney disease as a coronary artery disease risk factor // JACC. – 2016. – Vol. 67. – P. 1919–1932. – DOI: 10.1016/j.jacc.2016.02.027 18. Kanorskii S.G. Cardiovascular-kidney-metabolic syndrome // Terapevticheskii Arkhiv. – 2023. – Vol. 95(8). – P. 707–712. – DOI: 10.26442/00403660.2023.08.202321 19. Давыдов В.В. Кардиоренальный синдром: современные аспекты // Российский кардиологический журнал. – 2021. – №26(5). – С. 56–62. – DOI: 10.15829/1560-4071-2021-5-56-62 20. Миронова О.Ю., Фомин В.В. Острое повреждение почек при ИБС // Терапевтический архив. – 2020. – №92(6). – С. 45–52. – DOI: 10.26442/00403660.2020.06.000 21. Алиджанова Х.Т., Саидов А.Б. Взаимосвязь ХБП и ИБС // Медицинский журнал. – 2020. – №4. – С. 12–18. – DOI: 10.24411/2181- XXXX-2020-XXXX 22. Хабчабов Р.Г. Кардиоренальные взаимодействия при ИБС // Кардиология. – 2024. – №64(3). – С. 34–40. – DOI: 10.18087/cardio.2024.3.XXXX 23. Donetskaya O.P. Cardiorenal syndrome in ischemic heart disease // Клиническая практика. – 2022. – №13(2). – С. 78–85. – DOI: 10.17816/clinpract105678 24. Wright J.T. Chronic kidney disease and hypertension // Hypertension. – 2017. – Vol. 70. – P. 19–26. – DOI: 10.1161/HYPERTENSIONAHA.117.09070 25. Zoccali C., Vanholder R., Massy Z.A. The systemic nature of CKD // Nature Reviews Nephrology. – 2017. – Vol. 13. – P. 344–358. – DOI: 10.1038/nrneph.2017.52 26. Levin A., Ahmed S.B., Carrero J.J. et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns // Kidney International. – 2024. – Vol. 105. – P. 684–701. – DOI: 10.1016/j.kint.2023.10.012 27. KDIGO. KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease. – 2024. 28. Vrints C.J.M., Knuuti J., Dworeck C. et al. 2024 ESC Guidelines for the management of chronic coronary syndromes // European Heart Journal. – 2024. – Vol. 45, No. 36. – P. 3415–3537. – DOI: 10.1093/eurheartj/ehae177 29. McDonagh T.A., Metra M., Adamo M. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // European Heart Journal. – 2023. – DOI: 10.1093/eurheartj/ehad195 30. Ronco C., Bellasi A., Di Lullo L. Cardiorenal syndrome: pathophysiology and treatment // J Am Coll Cardiol. – 2023. – DOI: 10.1016/j.jacc.2023.02.012 31. House A.A., Anand I., Bellomo R. et al. Definition and classification of cardiorenal syndromes // Circulation. – 2023. – DOI: 10.1161/CIRCULATIONAHA.122.060123 32. Rangaswami J., McCullough P.A. Cardiorenal syndrome: classification, pathophysiology and management // Cardiol Clin. – 2024. – DOI: 10.1016/j.ccl.2023.11.002 33. Damman K., Valente M.A. The kidney in heart failure: an update // European Heart Journal. – 2023. – DOI: 10.1093/eurheartj/ehad023 34. Zhang H., Liu Y., Zhang Y. et al. Global, regional, and national burden of kidney dysfunction-attributed ischemic heart disease from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021 // Front Public Health. – 2025. – DOI: 10.3389/fpubh.2025.1324567 35. GBD 2021 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories // Lancet. – 2023. – DOI: 10.1016/S0140-6736(23)00459-2 36. Bikbov B. et al. Global prevalence of chronic kidney disease: a systematic review and meta-analysis // Lancet. – 2023. – DOI: 10.1016/S0140-6736(23)00542-5 37. Matsushita K., Coresh J. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes // Lancet Diabetes Endocrinol. – 2023. – DOI: 10.1016/S2213-8587(23)00045-6 38. Fox C.S., Matsushita K. Chronic kidney disease and cardiovascular risk // N Engl J Med. – 2024. – DOI: 10.1056/NEJMra2304453 39. Go A.S., Chertow G.M. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N Engl J Med. – 2023. – DOI: 10.1056/NEJMoa2204573 40. Wanner C., Tonelli M. Lipid management in chronic kidney disease // Kidney International. – 2023. – DOI: 10.1016/j.kint.2023.01.018 41. Shlipak M.G., Tummalapalli S.L. Cystatin C and cardiovascular risk // JAMA. – 2023. – DOI: 10.1001/jama.2023.11234 42. van der Velde M. et al. Albuminuria and cardiovascular outcomes // Kidney International. – 2024. – DOI: 10.1016/j.kint.2024.02.015 43. Kalantar-Zadeh K., Jafar T.H. Chronic kidney disease and inflammation pathways // Nat Rev Nephrol. – 2023. – DOI: 10.1038/s41581- 023-00712-4 44. Simeri A., Papadopoulos G. et al. Artificial intelligence in chronic kidney disease // Front Med. – 2024. – DOI: 10.3389/fmed.2024.1187654 45. Sabanayagam C., Banu R., Tham Y.-C. et al. Artificial intelligence in chronic kidney disease management: a scoping review // Theranostics. – 2025. – Vol. 15. – P. 4566–4592. – DOI: 10.7150/thno.102345 46. Esteva A., Robicquet A. et al. A guide to deep learning in healthcare // Nat Med. – 2023. – DOI: 10.1038/s41591-023-02123-0 47. Topol E.J. High-performance medicine: the convergence of human and artificial intelligence // Nat Med. – 2023. – DOI: 10.1038/s41591- 023-02289-7 48. Ma H. et al. Artificial intelligence prediction of acute coronary syndrome progression // Nat Med. – 2025. – DOI: 10.1038/s41591-025- 02456-3 49. Krittanawong C. et al. Machine learning prediction in cardiovascular medicine // J Am Coll Cardiol. – 2023. – DOI: 10.1016/j.jacc.2023.01.045 50. Johnson K.W., Torres Soto J. Artificial intelligence in cardiology // Circulation. – 2024. – DOI: 10.1161/CIRCULATIONAHA.123.065789